North Carolina State University is seeking a commercial partner to commercialize a new Anti-PD1 Antibody delivery microneedle patch.
More than 1 in 5 Americans will be diagnosed with a skin cancer in their lifetime. PD-1 is a cell surface receptor that belongs to the immunoglobulin superfamily and is expressed on T cells and pro-B cells. A new class of drugs that block PD-1, the PD-1 inhibitors, activate the immune system to attack tumors and are therefore used with varying success to treat some types of cancer. The delivery of anti-PD-1 Antibodies (APD1) for cancer treatment has met with varying success.
Researchers at North Carolina State University have developed an innovative self-degradable microneedle (MN) patch for the sustained delivery of aPD1 in a physiologically controllable manner. The microneedle is composed of biocompatible hyaluronic acid integrated with pH-sensitive dextran nanoparticles (NPs) that encapsulate aPD1 and glucose oxidase (GOx), which converts blood glucose to gluconic acid. The generation of acidic environment promotes the self-dissociation of NPs and subsequently results in the substantial release of aPD1. We find that a single administration of the MN patch induces robust immune responses in the B16F10 mouse melanoma model compared to MN without degradation trigger or intratumoral injection of free aPD1 with the same dose. Moreover, this administration strategy can integrate with other immunomodulators (such as anti-CTLA-4) to achieve combination therapy for enhancing anti-tumor efficacy.
About the Inventor
Dr. Zhen Gu is an Assistant Professor in the joint Department of Biomedical Engineering at North Carolina State University and the University of North Carolina at Chapel Hill. His work also supports the Molecular Pharmaceutics Division at the UNC Eshelman School of Pharmacy and Department of Medicine. His research interests include nanomedicine applications for anti-cancer and anti-diabetes as well as novel drug delivery formulations. Previously, Dr. Gu was a postdoctoral research scientist working with Dr. Robert Langer at the Massachusetts Institutes of Technology.